Studies Nieuws Nieuwsbrief Over ons Archief
Zoek beschikbare studies

Studieoverzicht

Study name: KRASCENDO

Histology NSCLC
Tumor stage Stage III - IV
Host / recruiting site 1 Radboud UMC Enrollment Recruiting
Host / recruiting site 2 Antoni van Leeuwenhoek Enrollment Recruiting
Therapy line First line (1L)
Design

This is an open-label, multicenter Phase Ib/II study designed to evaluate the safety, pharmacokinetics and activity of divarasib in combination with other cancer-therapies with untreated advanced or metastatic NSCLC that harbors a KRAS G12C mutation.

Intervention

Cohort A: Divarasib + Pembrolizumab
Cohort B: Divarasib + Pembrolizumab + Platinum-based chemotherapy + Pemetrexed
Key inclusion criteria
  • Unresectable advanced or metastatic KRAS G12C+ NSCLC
  • Non-squamous
  • Treatment naïve
Key exclusion criteria
  • Known concomitant second driver mutation with available targeted treatment.
  • Squamous cell histology, mixed tumors.
  • Symptomatic, untreated or actively progressing CNS metastases
Contact information